A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

The New York Times: Ozempic's Next Magic Trick: Treating Drug Addiction Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug ...

Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

Semaglutide and tirzepatides, the active ingredients in drugs including Mounjaro and Ozempic, have been hailed as a ...

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...

New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...

Early data suggests GLP-1 drugs, renowned for their ability to assist in weight loss, may have a powerful effect on treating ...